Literature DB >> 25645624

The royal wedding in chronic hepatitis B: The haves and the have-nots for the combination of pegylated interferon and nucleos(t)ide therapy.

Pietro Lampertico1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25645624     DOI： 10.1002/hep.27731

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  11 in total

Review 1.  Hepatitis B: Working Towards a Cure.

Authors:  Bianca W Chang; Aung Kaung; Lori Robbins; Tram T Tran
Journal:  Curr Gastroenterol Rep       Date:  2015-09

Review 2.  Approved Antiviral Drugs over the Past 50 Years.

Authors:  Erik De Clercq; Guangdi Li
Journal:  Clin Microbiol Rev       Date:  2016-07       Impact factor: 26.132

3.  Predictors for efficacy of combination therapy with a nucleos(t)ide analogue and interferon for chronic hepatitis B.

Authors:  Hong Li; Hua Wang; Cheng Peng; Xin Zheng; Jia Liu; Zhi-Hong Weng; Dong-Liang Yang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2017-08-08

4.  Phase IIb trial of in vivo electroporation mediated dual-plasmid hepatitis B virus DNA vaccine in chronic hepatitis B patients under lamivudine therapy.

Authors:  Fu-Qiang Yang; Gui-Rong Rao; Gui-Qiang Wang; Yue-Qi Li; Yao Xie; Zhan-Qing Zhang; Cun-Liang Deng; Qing Mao; Jun Li; Wei Zhao; Mao-Rong Wang; Tao Han; Shi-Jun Chen; Chen Pan; De-Ming Tan; Jia Shang; Ming-Xiang Zhang; Yue-Xin Zhang; Ji-Ming Yang; Guang-Ming Chen
Journal:  World J Gastroenterol       Date:  2017-01-14       Impact factor: 5.742

Review 5.  Drugs in Development for Hepatitis B.

Authors:  Altaf Dawood; Syed Abdul Basit; Mahendran Jayaraj; Robert G Gish
Journal:  Drugs       Date:  2017-08       Impact factor: 9.546

6.  Safety and efficacy of anti-PD-L1 therapy in the woodchuck model of HBV infection.

Authors:  Scott Balsitis; Volodymyr Gali; Pamela J Mason; Susan Chaniewski; Steven M Levine; Michael J Wichroski; Michael Feulner; Yunling Song; Karen Granaldi; James K Loy; Chris M Thompson; Jacob A Lesniak; Catherine Brockus; Narendra Kishnani; Stephan Menne; Mark I Cockett; Renuka Iyer; Stephen W Mason; Daniel J Tenney
Journal:  PLoS One       Date:  2018-02-14       Impact factor: 3.240

7.  HBsAg clearance in chronic hepatitis B patients with add-on pegylated interferon alfa-2a to ongoing tenofovir treatment: A randomized controlled study.

Authors:  Hamad Al Ashgar; Musthafa C Peedikayil; Mohammed Al Quaiz; Fahad Al Sohaibani; Abdulrahman Al Fadda; Mohammed Q Khan; Einar Thoralsson; Sahar Al Thawadi; Ahmed Al Jedai; Khalid Al Kahtani
Journal:  Saudi J Gastroenterol       Date:  2017 May-Jun       Impact factor: 2.485

8.  Expression of Interferon Effector Gene SART1 Correlates with Interferon Treatment Response against Hepatitis B Infection.

Authors:  Yong Li; Chuanlong Zhu; Faxi Wang; Tiantian Zhu; Jun Li; Shufeng Liu; Fei Xiao
Journal:  Mediators Inflamm       Date:  2016-12-18       Impact factor: 4.711

9.  Treatment of chronic hepatitis B naïve patients with a therapeutic vaccine containing HBs and HBc antigens (a randomized, open and treatment controlled phase III clinical trial).

Authors:  Mamun Al Mahtab; Sheikh Mohammad Fazle Akbar; Julio Cesar Aguilar; Gerardo Guillen; Euduaro Penton; Angela Tuero; Osamu Yoshida; Yoichi Hiasa; Morikazu Onji
Journal:  PLoS One       Date:  2018-08-22       Impact factor: 3.240

10.  A "sandwich" strategy for functional cure of chronic hepatitis B.

Authors:  Xuan-Yi Wang; Yu-Mei Wen
Journal:  Emerg Microbes Infect       Date:  2018-05-17       Impact factor: 7.163
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.